A group of scientific leaders and research funders are calling on Canada to develop a national strategy and action plan that would see the manufacturing, agri-food and health sectors share a new DNA-based technology as part of a robust and environmentally sustainable post-pandemic recovery.
“Canada needs to recognize that engineering biology is one of the disruptive technologies of the 21st century and requires focused support from government in collaboration with industry, involving all stakeholders in the ecosystem,” said Bettina Hamelin, president and CEO, Ontario Genomics, in announcing the release of a white paper at the Canadian Science Policy Conference November 16.
Authored by the National Engineering Biology Steering Committee and sponsored by Ontario Genomics, the document says Canada already has all the ingredients needed to grow a world-leading engineering biology ecosystem, including academic and industrial expertise, as well biofoundary “factories” for researching, testing and scaling-up new genetic products. Canada currently has a fully functioning biofoundry at Concordia University.
“However, the organization of a coherent network is lacking, and the fragmented approach taken so far has hindered the realization of Canada’s full potential in this field. We need to build a cohesive and fully integrated network that encompasses the Canadian engineering biology community to facilitate the discovery-to-commercialization pipeline across sectors, the creation of innovative start-ups, the renewal of traditional industries, and the development of talent and skills required for the biomanufacturing jobs of the future,” states Engineering Biology: A platform technology to fuel multi-sector economic recovery and modernize manufacturing in Canada.
Engineering (or synthetic) biology combines genomics and molecular biosciences with computing, automation, miniaturization, artificial intelligence, and the application of engineering principles to biological systems. This emerging platform technology makes it possible to use living cell-based and gene technologies to make what the white paper describes as “useful stuff” across nearly all sectors of the economy, including health (e.g. vaccines, diagnostics, engineered antibodies, and cell therapies); low-carbon manufacturing (e.g. textiles and bioplastics), and agriculture/agri-food (e.g. crop production, livestock, fermentation, and cellular agriculture).
A trillion dollar opportunity
The potential social and economic returns are significant. Other countries—namely the US, UK, Australia, China and Singapore—have invested heavily in this emerging sector, which is forecast by the McKinsey Global Institute to generate US$2-$4 trillion in global value between 2030-2040. Released in May, that same report estimates that as much as 60% of the physical inputs to the global economy could be produced biologically, with biological materials such as wood representing about one-third of these inputs. Additional, 45% of the world’s disease burden could be addressed through engineering biology and 30% of private sector R&D could be spent on biology related industries.
The Steering Committee wants a national strategy and action plan led by a new organization called the Canadian DNA Engineering Systems Network. Can-DESyNe brings together nearly 90 small and large companies, academia, institutions, associations and government partners focused on applying bio-design and biotech processes to health, agriculture, food and industrial products sectors. With additional funding, the white paper says the network can:
The white paper also recommends creating legal, ethical and regulatory conditions that enable the rapid and safe approval of new technologies.
National Engineering Biology Steering Committee |
Dr. Bettina Hamelin, President and CEO, Ontario Genomics (Chair) |
Andrew Casey, President and CEO, BIOTECanada |
Dr. Doane Chilcoat, Leader, Applied Science and Technology, Corteva Agriscience |
Dr. Lakshmi Krishnan, Acting VP, Life Sciences, National Research Council |
Dr. Krishna Mahadevan, Professor, University of Toronto |
Dr. Vincent Martin, Director, Centre for Applied Synthetic Biology, Concordia University |
Dr. Keith Pardee, Canada Research Chair in Synthetic Biology in Human Health, University of Toronto |
Dr. Steve Webb, Executive Director and Chief Executive Officer, Global Institute for Food Security |
Dr. Peter Zandstra, Director, Michael Smith Laboratories, University of British Columbia |
Observers |
Pari Johnston, Vice-President, Policy and Public Affairs, Genome Canada |
Dr. Yale Michaels, Banting Postdoctoral Fellow and Michael Smith Foundation for Health Research Trainee |
Amy Yeung, CSBERG Director of Leadership Development, cGEM Co-Founder and Co-Director |
R$